Condition
Calcific Uremic Arteriolopathy
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
P 3 (2)
Trial Status
Completed3
Recruiting2
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04592640Early Phase 1Recruiting
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
NCT02527213Phase 3Withdrawn
Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy
NCT03032835Recruiting
Partners Calciphylaxis Biobank
NCT04195906Phase 3Completed
Phase 3 Study of SNF472 for Calciphylaxis
NCT02278692Not ApplicableCompleted
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
NCT02790073Phase 2Completed
Phase 2 Study With SNF472 in Calciphylaxis Patients
Showing all 6 trials